Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer

By LabMedica International staff writers
Posted on 07 Oct 2019
Researchers have shown that microRNAs present in semen exosomes can serve as biomarkers for the non-invasive diagnosis of prostate cancer.

Exosomes are a type of extracellular vesicle (EV), a class that also includes microvesicles and apoptotic bodies. More...
EVs are cell-derived lipid-bilayer-enclosed structures, with sizes ranging from 30 to 5,000 nanometers. In the past decade, EVs have emerged as important mediators of cell communication because they serve as vehicles for the intercellular transmission of biological signals (proteins or nucleic acids) capable of altering cell function and physiology.

MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. MiRNAs resemble siRNAs of the RNA interference (RNAi) pathway, except miRNAs derive from regions of RNA transcripts that fold back on themselves to form short hairpins, whereas siRNAs derive from longer regions of double-stranded RNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. Furthermore, miRNAs play essential roles in tumor development, are stable under diverse analytical conditions, and can be readily detected in body fluids.

Although it is specific for prostate tissue, serum prostate-specific antigen (PSA) screening has resulted in an over-diagnosis of prostate cancer and many unnecessary biopsies of benign disease due to a well-documented low cancer specificity. Therefore, improved diagnostic methods are required.

In this regard, investigators at the Bellvitge Biomedical Research Institute (Barcelona, Spain) suggested that semen could be considered a liquid biopsy of the organs of male reproductive system and specifically of prostate gland, since approximately 40% of semen is derived from prostatic tissue, so that its contents are most likely to contain prostate disease-specific derived molecules.

To test this theory, the investigators profiled the expression level of miRNAs contained in semen exosomes from men with moderately increased PSA levels to assess their usefulness, either alone or in addition to PSA marker, as non-invasive biomarkers for the early efficient diagnosis and prognosis of prostate cancer.

The investigators reported that an altered miRNA expression pattern was detected by high throughput profiling analysis of prostate cancer patients when compared with healthy individuals’exosomal semen samples. The presence of vasectomy was taken into account for the interpretation of results. Fourteen miRNAs were selected for miRNA validation as prostate cancer biomarkers in a subsequent set of semen samples. The pathway analysis of predicted miRNA target genes supported a role for these miRNAs in prostate cancer diagnosis and/or progression.

"Our study shows semen exosome miRNA-based models as molecular biomarkers with the potential to improve prostate cancer diagnosis/prognosis efficiency. These miRNA-based tests should provide reliable information that will help physicians to take clinical decisions as well as will save unnecessary invasive biopsies to the patients, improving the efficiency of detection of prostate cancer and patient outcome," said senior author Dr. Sara Larriba, a principle investigator at the Bellvitge Biomedical Research Institute. "Our aim is to offer our results to the clinics as a diagnostic test. In that respect, as our next step, we should carry out further prospective studies on larger cohorts of patients before this miRNA-based biomarker could be adopted in the daily clinical practice."

The semen exosome study was published in the September 24, 2019, online edition of the journal Scientific Reports.

Related Links:
Bellvitge Biomedical Research Institute


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
Specimen Radiography System
TrueView 200 Pro
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.